A Randomized Comparison of Platelet Inhibition Using a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Prior Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-6 Study
Phase of Trial: Phase IV
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs Ticagrelor (Primary) ; Clopidogrel
- Indications Coronary artery disease
- Focus Pharmacodynamics
- Acronyms OPTIMUS-6
- 02 Oct 2019 Planned End Date changed from 1 Nov 2019 to 1 Jan 2020.
- 02 Oct 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Nov 2019.
- 05 Apr 2019 Planned End Date changed from 1 Jul 2019 to 1 Nov 2019.